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Metastasis	depends	on	the	ability	of	tumor	cells	to	establish	a	relationship	with	the	newly	seeded	tissue	that	is	
conducive	to	their	survival	and	proliferation.	However,	the	factors	that	render	tissues	permissive	for	metastatic	
tumor	growth	have	yet	to	be	fully	elucidated.	Breast	tumors	arising	during	pregnancy	display	early	metastatic	
proclivity,	raising	the	possibility	that	pregnancy	may	constitute	a	physiological	condition	of	permissiveness	
for	tumor	dissemination.	Here	we	have	shown	that	during	murine	gestation,	metastasis	is	enhanced	regard-
less	of	tumor	type,	and	that	decreased	NK	cell	activity	is	responsible	for	the	observed	increase	in	experimental	
metastasis.	Gene	expression	changes	in	pregnant	mouse	lung	and	liver	were	shown	to	be	similar	to	those	
detected	in	premetastatic	sites	and	indicative	of	myeloid	cell	infiltration.	Indeed,	myeloid-derived	suppressor	
cells	(MDSCs)	accumulated	in	pregnant	mice	and	exerted	an	inhibitory	effect	on	NK	cell	activity,	providing	a	
candidate	mechanism	for	the	enhanced	metastatic	tumor	growth	observed	in	gestant	mice.	Although	the	func-
tions	of	MDSCs	are	not	yet	understood	in	the	context	of	pregnancy,	our	observations	suggest	that	they	may	
represent	a	shared	mechanism	of	immune	suppression	occurring	during	gestation	and	tumor	growth.
Introduction
Metastasis is a multistage process that constitutes the primary cause 
of cancer-related death. It requires cells to detach from the primary 
tumor mass, migrate toward and invade lymphatic or blood vessels, 
survive within the circulation, attach to the endothelium of distant 
organs, penetrate the endothelial barrier, and establish new tumor 
colonies (1). The process is highly inefficient, as less than 0.1% of 
tumor cells that penetrate the circulation end up forming metastat-
ic colonies (2, 3), but the explanation for the observed inefficiency 
of metastasis is still largely obscure. Several possible reasons have 
been invoked, including tumor cell destruction by shear stress and 
immune cells in the circulation (4), and it is clear that large numbers 
of tumor cells can penetrate distant organs only to undergo apop-
tosis or enter a state of dormancy that may extend for an indefinite 
period of time (5). Mechanisms underlying dormancy are unclear, 
although recent observations suggest that the new microenviron-
ment may prevent tumor cells from proliferating while allowing 
them to survive, or, alternatively, that immune surveillance may 
keep micrometastases in check (6). Over time, modifications in the 
host microenvironment — including the recruitment and function 
of cells of the immune system — that occur as a result of a variety of 
physiological events, including aging, may relieve the pressure on 
the metastatic foci, allowing them to expand and ultimately form 
clinically relevant macrometastases (7).
Recent evidence suggests that tumor cells may be able to direct 
the formation of premetastatic niches in selected organs by 
secreting or by inducing stromal cell secretion of cytokines or 
growth factors — collectively described as tumor-derived soluble 
factors (TDSFs) — that render selected target organ microenvi-
ronments permissive for the implantation and subsequent out-
growth of disseminating tumor cells (8, 9). A major constituent 
of premetastatic niches are bone marrow–derived cells (BMDCs), 
which promote local tumor cell establishment by secreting che-
moattractants (10, 11), producing proteases that facilitate tumor 
cell infiltration of the target organ and elaborating extracellular 
matrix components that further help recruit BMDCs or tumor 
cells to these sites (9, 12). Enhanced lung metastasis may also 
result from experimental allergen-induced lung leukocyte infil-
tration and asthma has been shown to be prevalent in breast can-
cer patients with lung metastases (13).
Tumors also need to escape immune surveillance to grow at pri-
mary as well as at metastatic sites (14). One of the possible results 
of immunoediting, a process that shapes tumor cell immune 
resistance by selective pressure of the immune system itself, is the 
accumulation of cells of the myelomonocytic lineage that harbor 
immunosuppressive functions and repress antitumor immunity. 
This heterogeneous cell population of myeloid-derived suppres-
sor cells (MDSCs) expands not only in the context of cancer 
(driven by TDSFs), but also during situations such as infection, 
autoimmune disease, vaccination, and trauma (15, 16).
Pregnancy is a physiological state of dampened cellular immu-
nity in the context of maternal immune tolerance toward the 
semiallogenic conceptus (17). Several mechanisms are involved 
in preventing rejection of fetal tissues, including, among others, 
lack of classical class I MHC molecules on the surface of fetal 
cells, expression of NK cell– and T cell–modulating HLA-G mol-
ecules, hyporesponsiveness of immune cells as a result of indole-
amine 2,3-dioxygenase activity and specific silencing of alloreac-
tive T cells by regulatory T cells (18). MDSC activity, however, has 
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not been invoked in this context. Pregnancy-associated cancers 
(usually defined as malignancies diagnosed during pregnancy or 
within 1 year of parturition) do not generally differ in outcome, 
although there is some debate in the case of melanomas. How-
ever, the worse prognosis of pregnancy-associated breast cancer 
(PABC) is widely recognized but the underlying mechanisms 
remain obscure. Explanations including delayed diagnosis and 
putative tumor-promoting properties of the involuting mamma-
ry gland (19) have been proposed to result in increased stage at 
diagnosis. A relationship between enhanced metastatic proclivity 
of PABC and decreased cellular immunity has been suggested, 
but without firm experimental support so far (20).
A mouse model of increased experimental metastasis during 
gestation has been described (21), where the difference com-
pared with nonpregnant littermates was ascribed to increased 
platelet-tumor cell aggregation that promotes tumor cell sur-
vival and hence enhances metastatic growth. Our present obser-
vations indicated that murine gestation augmented the rate 
and the degree of tumor dissemination, regardless of tumor cell 
origin. Moreover, we showed that decreased NK cell numbers 
and cytotoxicity led to blunted local clearing of tumor cells and 
demonstrated that MDSCs contributed to the reduced NK activ-
ity and corresponding enhancement of tumor dissemination. 
Furthermore, we provided evidence that pregnancy induced 
Figure 1
Pregnant mice develop more metastases upon tail vein injection (TVI) of B16.F10 cells. Luciferase-expressing B16.F10 tumor cells (5 × 105) 
were injected into the tail vein of 16-day pregnant and virgin NOD/SCID mice. (A) Evolution of the bioluminescence signal from the entire body 
surface of supine mice after i.p. administration of luciferin. Data are mean ± SEM. ***P < 0.001, 2-way repeated-measures ANOVA. (B) Repre-
sentative macroscopic images of lung and liver metastases in formalin-fixed organs. Scale bars: 5 mm. (C) Organ distribution of metastases, as 
determined by necropsy 17 days after tumor cell injection. Blue, virgin; pink, pregnant. (D) Representative lung histology. Scale bar: 1 mm. P, 
pregnant; V, virgin. (E) Morphometry of lung sections (5 fields per section, 1 section per mouse). ***P < 0.001, 2-tailed unpaired t test.
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metastasis-promoting changes in the lung and liver microen-
vironment, as revealed by the striking similarities between gene 
expression profiles of pregnant mouse organs and premetastatic 
organs in cancer-bearing mice.
Results
Pregnant mice develop a greater number of metastases than do their vir-
gin counterparts upon i.v. injection of B16.F10 melanoma cells. B16.F10 
melanoma cells were engineered to stably express firefly luciferase 
and were injected into the tail vein of 16-day pregnant and virgin 
NOD/SCID mice. Tumor cell injection around day 16 of murine 
gestation has previously been shown to lead to maximal enhance-
ment of metastasis load (21). Biweekly bioluminescence imaging 
revealed a consistently higher tumor load in pregnant animals, 
culminating in 5- to 10-fold greater signal intensity than in virgin 
mice 17 days after tumor cell injection (Figure 1A). At this time 
point, mice were sacrificed, and examination at necropsy con-
firmed a strikingly greater tumor load in pregnant mice (Figure 1, 
B and C), consistent with the bioluminescence signals. In organs 
such as lungs that displayed metastatic colonies in both sets of 
animals, the size and frequency of the colonies were significantly 
greater in pregnant mice, as determined by quantifying metastatic 
lesions on lung sections (Figure 1, D and E). In addition, organs 
including liver and abdominal lymph nodes that were metastasis-
free in virgin mice contained numerous metastases in the majority 
of pregnant animals (Figure 1C). Mammary glands in pregnant 
mice also harbored more metastases than in virgin animals, and in 
all organs, metastatic lesions tended to be larger in pregnant mice. 
Thus, the number, size, and degree of dissemination of tumor 
colonies were markedly increased during pregnancy.
Metastasis is enhanced in pregnant mice regardless of tumor cell type, 
mode of injection, and mouse strain. To determine whether the 
observed increase in B16.F10 cell dissemination in pregnant mice 
is a general or cell type–restricted phenomenon, we injected lucifer-
ase-expressing human fibrosarcoma HT1080 cells and melanoma 
MDA-MB-435 cells into the tail vein of virgin and 16-day pregnant 
immunocompromised NOD/SCID mice and assessed metastasis 
development over a 30- to 50-day period after injection (Figure 2, 
A–D, and Supplemental Figure 1, A–D; supplemental mate-
rial available online with this article; doi:10.1172/JCI41936DS1). 
Similar to experiments using B16.F10 cells, pregnant mice bearing 
HT1080 and MDA-MB435 cells displayed significantly higher bio-
luminescence, which reflected a greater number and size of lung 
metastases from both cell lines. When the mouse lymphoma cell 
line Yac-1 was tested in experimental metastasis assays, pregnant 
NOD/SCID mice also had increased tumor cell load and suc-
cumbed earlier than virgin mice (Supplemental Figure 1E). Finally, 
tail vein injection of luciferase-expressing TA3 mouse mammary 
carcinoma cells into syngeneic, fully immunocompetent virgin 
or pregnant A/Jax mice, as well as injection of B16.F10 cells into 
C57BL/6 mice, attested that increased experimental metastasis in 
pregnant mice was not restricted to a given cell line, tumor type, 
mouse strain, or immunocompromised background (Figure 2, 
E–H, and see below).
Whereas the experimental metastasis model based on tail vein 
injection of tumor cells allowed demonstration of the difference 
in late-stage metastatic tumor growth, it did not provide evidence 
that development of spontaneously occurring metastases was 
affected. We therefore selected a model in which this issue could be 
addressed in vivo. Lewis lung carcinoma (LCC) cells were injected 
s.c. into syngeneic virgin mice, and half the animals were mated 
within hours of injection. After 11 days, primary tumors had 
reached 8–9 mm in diameter and were surgically resected, and the 
metastasis load was monitored biweekly by bioluminescence imag-
ing (Figure 2I). Consistent with what was observed after tail vein 
injection, a greater signal intensity was recorded in pregnant mice, 
corresponding to a larger size of lung metastases in a higher num-
ber of animals at necropsy (Figure 2, J and K). Similar results were 
obtained using B16.F10 cells in C57BL/6 mice (data not shown)
Pregnancy does not affect in vitro and in vivo tumor cell growth. To 
address the possible effects of pregnancy-associated circulating 
factors on the observed differences in tumor cell dissemination, 
we determined the expression of estrogen receptor (ER) and pro-
gesterone receptor (PR) on B16.F10, HT1080, MDA-MB-435, TA3, 
and LLC cells. Immunohistochemical analysis of lung metastases 
derived from the 5 cell lines failed to reveal detectable expression 
of either hormone receptor (Supplemental Figure 2A). We next 
assessed the response of the tumor cell lines to serum from virgin 
and pregnant NOD/SCID mice. As expected, mouse serum–stim-
ulated cell proliferation compared to that of serum-free culture 
medium (Figure 3A). However, there was no significant difference 
between the effect of serum derived from virgin and pregnant mice 
in the case of B16.F10 and HT1080 cells; with MDA-MB435 and 
Yac-1 cells, pregnant mouse–derived serum had a weaker effect on 
tumor cell proliferation than did serum from virgin mice. Similar 
observations were made when plasma extracted from pregnant 
or virgin mice was used (data not shown). To compare primary 
tumor growth, B16.F10, HT1080, and MDA-MB435 tumor cells 
were injected s.c. into virgin and 4-day pregnant NOD/SCID 
mice, and tumor growth was assessed 12 days later. Similarly, s.c. 
injection of 5 × 105 LLC cells into virgin C57BL/6 mice was done 
immediately before breeding, and tumor growth was monitored 
for 11 days before resection. No significant difference was found 
in tumor size between pregnant and virgin animals (Figure 3B). 
Finally, staining of lung sections from virgin and pregnant mice 
3, 6, and 10 days after tail vein injection of the MDA-MB-435 cell 
line failed to reveal differences in the number of cells expressing 
the (human) proliferation marker Ki67 (Supplemental Figure 2B). 
Taken together, these findings argue against a purely growth-pro-
moting effect of pregnancy on the injected tumor cells.
Tumor cell clearance from lungs after tail vein injection is distinct in virgin 
and pregnant mice. Based on the observations that in vitro growth and 
s.c. tumor forming capacity of the cells used in these experiments 
were unaffected by circulating factors associated with pregnancy, we 
reasoned that the explanation for the observed enhancement of dis-
seminated tumor growth in experimental metastasis assays is most 
likely related to changes specifically affecting circulating tumor cells 
or those immobilized in the target organs. To address factors that 
may enhance permissiveness for tumor dissemination during preg-
nancy, we sought to determine the time point at which a disparate 
evolution could first be detected, eventually leading to the massive 
difference in tumor load at necropsy. GFP-expressing HT1080 cells 
(1–2 × 106 cells) were injected i.v. into virgin and 16-day pregnant 
NOD/SCID mice, and fluorescence stereomicroscopy was performed 
on lungs 1, 6, and 24 hours as well as 4 days following injection. After 
initially comparable lung fluorescence in both conditions, signal 
intensity began to diminish in virgin compared with pregnant mice 
as early as 6 hours after injection (Figure 4). The difference was clear 
at 24 hours; by 4 days, there was virtually no fluorescent signal from 
lungs of virgin mice, whereas the signal from lungs of pregnant mice 
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Figure 2
Increased metastasis in pregnant mice is independent of tumor cell type and mouse strain and holds true for spontaneous metastasis formation. 
(A–D) 7 × 105 luciferase-expressing HT1080 tumor cells were injected into the tail vein of day-16 pregnant and virgin NOD/SCID mice. (E–H) 
7 × 105 luciferase-expressing TA3 tumor cells were injected into the tail vein of syngeneic day-16 pregnant and virgin A/Jax mice. (I–K) 5 × 105 
luciferase-expressing LLC cells were injected s.c. into 21 virgin C57BL/6 mice, then breeding was started, yielding 13 pregnant animals. Primary 
tumors were resected 11 days after injection, and mice were followed up for lung metastasis development for 33 days. (A, E, and I) Evolution of 
the bioluminescent signal from the entire body surface of mice. *P < 0.05, **P < 0.01, ***P < 0.001, 2-way repeated-measures ANOVA with Bon-
ferroni post-test. (B, F, and J) Representative images of formalin-fixed lungs. Scale bars: 5 mm. (C and G) Histomorphometry of lung sections (4 
fields per mouse). **P < 0.01, ***P < 0.001, unpaired 2-tailed t test. (D and H) Representative lung histology. Scale bars: 1 mm. (K) Proportion 
of mice with macroscopic lung metastases. *P < 0.05, column statistics.
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displayed markedly increased intensity compared with the early time 
points (Figure 4). Similar, albeit not as striking, results were observed 
using GFP-expressing MDA-MB-435 and B16.F10 cells (Supplemen-
tal Figure 3 and data not shown). The differential decrease in the 
fluorescent signal emitted by pregnant and virgin mouse lungs was 
consistent with decreased tumor cell clearing from the lungs of preg-
nant mice within the first hours and days after injection.
Quantitative and qualitative changes in NK cells are responsible for 
increased metastatic growth in pregnant mice. The differential clearing 
of tumor cells from the lungs of virgin and pregnant mice prompt-
ed us to address the possible contribution of the immune system. 
As NOD/SCID mice are deficient in adaptive immunity, and NK 
cells are their first line of defense against tumor cells, we compared 
the number and activity of NK cells in virgin and 16-day pregnant 
NOD/SCID mice. Quantification was achieved by flow cytomet-
ric analysis of CD49b+ and NKG2D+ or NKp46+ cells (Figure 5A). 
Whereas NK cells represented a lower percentage of total leuko-
cytes in the spleen and blood of pregnant mice than that in virgin 
mice, the proportions in lung and liver were comparable, albeit 
with a tendency to decrease in pregnant mice as well (Figure 5, 
B and C). The slight decrease of the NK cell population in the liver 
and lung of pregnant mice could also be appreciated on frozen sec-
tions using an anti-NKp46 antibody (Supplemental Figure 4A).
The importance of NK cell function in controlling metastasis has 
long been recognized (22). However, to our knowledge, no direct 
link has been established between decreased NK numbers and 
function in pregnant mice and increased experimental metasta-
sis. We therefore investigated whether depletion of NK cells might 
abolish the difference in metastasis load between pregnant and 
virgin NOD/SCID mice. We used 3 different strategies of NK cell 
depletion (Figure 5D): nonspecific leukocyte depletion by sublethal 
whole-body irradiation, which reduced NK cell counts in periph-
eral blood of virgin and 16-day pregnant NOD/SCID mice about 
30-fold; specific NK cell depletion by anti–asialo GM1 (AAGM1) 
antibody, which resulted in a 4-fold (pregnant) to 15-fold (virgin) 
reduction in NK cell counts; and use of Il-2 receptor common 
γ subunit knockout (cg KO) NOD/SCID mice, which had no NK 
development at all. Upon B16.F10 tumor cell injection, the absence 
(cg KO mice) or near-complete depletion (irradiated mice) of NK 
cells resulted in overall increased metastasis take (Figure 5E), with 
liver metastases developing in virgin animals as well, and in the 
abrogation of any difference in tumor cell load between pregnant 
and virgin NOD/SCID mice. Consistent with this notion, virgin 
and pregnant cg KO NOD/SCID mice developed comparable 
metastatic disease upon tail vein injection of HT1080 and MDA-
MB-435 tumor cells (Figure 5, F and G). Similarly, fluorescence 
stereomicroscopy of lungs of 16-day pregnant and virgin cg KO 
NOD/SCID mice at different time points after the injection of 
GFP-expressing HT1080 cells showed very limited tumor cell clear-
ance from the lung microvasculature in the absence of NK cells 
and, more importantly, no difference between pregnant and virgin 
animals (Supplemental Figure 4B). However, AAGM1-treated vir-
gin mice still developed significantly less metastases than did their 
pregnant counterparts, despite a greater reduction in NK numbers 
(Figure 5, D and E). It appears, therefore, that changes in NK cell 
cytotoxicity — and not merely decreased NK cell numbers — may 
be primarily responsible for enhanced B16.F10 metastasis in preg-
nant NOD/SCID mice. To determine NK activity, standard 51Cr 
Figure 3
Gestation has no direct effect on tumor cell growth. (A) MTT cell proliferation assay on the indicated cells grown for 48 hours in the presence of 
FBS-free culture medium supplemented with 15% fresh mouse serum or plasma extracted from virgin and 16-day pregnant NOD/SCID mice. 
**P < 0.01, ***P < 0.001. (B) 2 × 105 B16.F10, 7.5 × 105 HT1080, or 5 × 105 MDA-MB-435 cells were injected s.c. into 4-day pregnant and virgin 
NOD/SCID mice. For the experiment with LLC, 5 × 105 cells were injected into 11 virgin C57BL/6 mice, and mating was started the same day, 
yielding 8 pregnant mice. Tumors were resected and weighed 12 days (11 days for LLC) after injection. Horizontal bars denote medians.
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release assays were performed on Yac-1 target cells using spleno-
cytes extracted from poly(I:C)-stimulated 16-day pregnant or virgin 
NOD/SCID mice. Flow cytometry — adjusted for NK proportions 
among splenocytes — revealed an approximately 8-fold reduction 
in mean NK cell cytotoxicity in splenocytes derived from pregnant 
mice (Figure 5H). Taken together, these observations suggest that 
the mechanism whereby pregnancy leads to increased experimen-
tal metastasis is related to reduced NK cell–mediated clearance of 
tumor cells within hours of their injection.
NK cell impairment underlies increased metastasis in pregnant immu-
nocompetent C57BL/6 mice. Whereas use of NOD/SCID mice in 
this experimental metastasis model had the advantage of facili-
tating the elucidation of the role of innate immunity in mediat-
ing increased metastasis in pregnant mice as well as allowing 
xenografting of human tumor cell lines, the involvement of an 
immune-based mechanism warranted validation in a more physi-
ological context using immunocompetent C57BL/6 mice. Injec-
tion of syngeneic B16.F10 melanoma cells i.v. into 16-day pregnant 
and virgin C57BL/6 mice led to an overall higher metastasis load 
in pregnant animals (Figure 6A), similar to the difference observed 
in NOD/SCID mice.
B16.F10 melanoma cells were originally isolated from C57BL/6 
mice and have been reported to be sensitive to NK cell killing. In 
order to address the question of how much of the difference in 
metastasis development can be ascribed to reduced NK function in 
pregnant C57BL/6 mice, we repeated the experiment with the syn-
geneic lymphoma cell lines RMA and EL4, which are both known 
to be resistant to NK cell–mediated cell cytotoxicity. The difference 
in metastasis take between pregnant and virgin mice was greatly 
reduced and did not reach statistical significance when these 2 cell 
lines were used (Figure 6, B and C). Nevertheless, a residual increase 
in tumor cell load was still apparent, possibly indicating that fac-
tors other than NK function — such as suppressed T cell activity 
— are implicated in increasing metastasis take in immunocompe-
tent pregnant mice. Using flow cytometry, we found no significant 
difference in NK cell proportions in blood, spleen, and lung of 16-
day pregnant C57BL/6 mice (Supplemental Figure 5). Decreased 
NK cell cytotoxicity in pregnant C57BL/6 mice was also confirmed 
using splenocytes in a standard 51Cr release assay (Figure 6D).
MDSC accumulation in pregnant mice contributes to increased host per-
missiveness to metastasis. Whereas dampened cellular immunity is an 
acknowledged feature of pregnancy-associated immune adaptation, 
little is known about how systemic NK cell function is regulated 
during pregnancy (17). On the other hand, MDSCs have previously 
been shown to inhibit NK cytotoxicity in tumor-bearing mice as 
well as in cancer patients (23–25). We therefore assessed whether the 
well-known expansion of granulocytic populations and increased 
leukocyte counts associated with pregnancy (26) could reflect, at 
least in part, the accumulation of such immunosuppressive cells. In 
mice, MDSCs are characterized by coexpression of CD11b and Gr-1 
(27). Using flow cytometry, we found that spleen, peripheral blood, 
lung, and liver of pregnant NOD/SCID mice harbored significantly 
higher proportions of CD11bhiGr-1+ cells than did those derived 
from virgin mice (Figure 7A). Similar observations were made upon 
Gr-1 staining of lung and liver sections (Supplemental Figure 6A). 
CD11bhiGr-1hi subsets constituted the major expanded fraction 
(Figure 7B), which could further be characterized as Ly-6C–Ly-6G+ 
cells (Supplemental Figure 6B). Accumulation of these cells with 
granulocytic morphology was also evident on blood smears and dif-
ferential white blood cell counts (compare with control animals in 
Supplemental Figure 6I). Similarly, increased granulocyte propor-
tions were detected in pregnant C57BL/6 mice, and CD11bhiGr-1+ 
cells — in particular, CD11bhiGr-1hi fractions — accumulated in 
blood and spleen of these animals compared with their virgin coun-
terparts (Supplemental Figure 6, C–E). Finally, the 3 cell popula-
tions consisting of NK, CD11bhiGr-1hi, and CD11bhiGr-1lo cells were 
monitored in the circulation throughout NOD/SCID gestation and 
in littermate virgin mice in parallel, beginning 3 days after mating 
and ending 4 days after parturition in the former, with examination 
of a blood sample every 3–4 days. In order to avoid confounding fac-
tors that may be caused by repetitive blood sampling in an animal, 
the results were expressed as a ratio of pregnant to virgin mouse 
cell population. MDSC (CD11bhiGr-1hi more than CD11bhiGr-1lo) 
levels rose during pregnancy, reaching a peak around day 14, and 
remained elevated for at least 4 days after parturition. NK levels 
started dropping from around day 6 of pregnancy, reaching a nadir 
just before parturition, and returned to normal proportions within 
days after giving birth (Supplemental Figure 6F).
Figure 4
Differences in tumor cell load 
become apparent early after injec-
tion. Fluorescence stereomicrosco-
py of lungs at indicated time points 
after tail vein injection of 1–2 × 106 
GFP-expressing HT1080 tumor 
cells into virgin and 16-day preg-
nant NOD/SCID mice. Exposure 
time was constant. Original magni-
fication, ×0.71.
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Since MDSCs are defined not only by their double-positive 
staining for CD11b and Gr-1, but also — and more importantly 
— by their functional capacity to inhibit cellular immunity and 
especially T cell function, we cocultured CD11bhiGr-1hi cells 
extracted from pregnant and virgin C57BL/6 spleens using Ly-
6G–coated magnetic microbeads with T cells purified from spleen 
and lymph nodes of virgin C57BL/6 mice using CD90.2-coated 
magnetic microbeads. T cells that were in contact with Ly-6G+ 
cells from pregnant mice displayed up to 4-fold suppressed 
proliferation dependent on T cell/MDSC ratios, as assessed by 
3H-thymidine incorporation and CFSE labeling assays (Figure 7C 
and Supplemental Figure 6G). Accordingly, Il-2 secretion was 
Figure 5
Quantitative and qualitative changes in NK cells are responsible for increased metastatic spread of tumors in 16-day pregnant versus virgin NOD/
SCID mice. (A) Representative FACS images of NK cell quantification in splenocytes (CD49b+NKG2D+ in forward scatter/side scatter leukocyte 
gate). (B) Quantification of NK cells in blood and spleen by FACS analysis for CD49b+NKG2D+ cells. *P < 0.05, **P < 0.01. (C) Quantification 
of NK cells in lung and liver single-cell suspensions by FACS analysis for CD49b+NKp46+ cells among CD45+ cells. (D and E) Control (rabbit 
IgG; rb IgG), NK-depleted (AAGM1), sublethally irradiated (2.7–3.0 Gy), and cg KO NOD/SCID mice were subjected to NK cell quantification in 
tail vein blood prior to tail vein injection of 1 × 105 luciferase-expressing B16.F10 tumor cells. Shown are (D) absolute NK numbers in tail vein 
blood by FACS analysis and total leukocyte counting prior to tumor cell injection and (E) bioluminescence imaging. Data are from 6–10 mice per 
condition. *P < 0.05, ***P < 0.001. (F and G) Tail vein injection of 1 × 105 luciferase-expressing HT1080 (F) and MDA-MB-435 (G) tumor cells 
into cg KO NOD/SCID mice and bioluminescence imaging. (H) Standard 4-hour 51Cr release cytotoxicity assay with splenocytes extracted from 
poly(I:C)-stimulated pregnant and virgin NOD/SCID mice and Yac-1 target cells. Graph was adjusted for NK proportions in splenocytes, as 
determined by flow cytometry. 4 mice were used per condition.
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reduced by 30% compared with T cells that were cocultured with 
virgin mouse–derived Ly-6G+ cells (Supplemental Figure 6H). Of 
note, Ly-6G+ cells from virgin mice also suppressed proliferation 
and Il-2 secretion of T cells compared with T cells that had not 
been cocultured, albeit to a much lesser extent than pregnant 
mouse–derived MDSCs, suggestive of some immunoregulatory 
properties of Ly-6G+ cells derived from naive mice as well. IFN-γ 
was slightly diminished in T cells exposed to pregnant compared 
with virgin Ly-6G+ cells, whereas there was no difference in Il-10 
production (data not shown).
We next investigated whether CD11bhiGr-1hi cells contribute to 
reduced NK cell cytotoxicity in pregnant NOD/SCID mice. Ly-6G+ 
cells extracted from pregnant and virgin NOD/SCID splenocytes 
(Supplemental Figure 6B) and NK cells isolated from naive NOD/
SCID female spleens using CD49b-coated magnetic microbeads 
were cocultured before subjecting the cell mix to standard 51Cr 
release cytotoxicity assays using Yac-1 target cells. NK cells exposed 
to Ly-6G+ MDSCs from pregnant mice exhibited approximately 33% 
reduced cytotoxicity (Figure 7D).
To determine the functional effect of MDSCs on metastasis, we 
depleted virgin and pregnant mice of these cells using anti-Gr1 
RB6-8C5 antibody. Peripheral blood smears immediately pre-
ceding B16.F10 tumor cell injection revealed robust depletion 
of granulocyte fractions (Supplemental Figure 6I). Injection of 
tumor cells after MDSC depletion resulted in unaltered metas-
tasis in virgin mice, but significantly reduced metastasis in preg-
nant mouse lungs (Figure 7, E and F, and Supplemental Figure 6I). 
Conversely, adoptive transfer of Ly-6G+ spleen-derived cells prior 
to Yac-1 tumor cell injection resulted in increased metastasis load 
in animals receiving MDSCs isolated from pregnant NOD/SCID 
mice compared with those receiving Ly-6G+ cells from virgin mice 
(Supplemental Figure 6K).
Gene expression profiles of pregnant and virgin mouse lung and liver reveal 
similarities to premetastatic niche signatures and predict outcome of patients 
with lung cancer. In parallel to investigating changes in the immune 
system that favor tumor cell dissemination during murine gestation, 
we sought to determine whether pregnancy also affects the target 
organ microenvironments, thereby generating a more metastasis-
permissive “soil.” We assessed gene expression profile changes in the 
lung and liver of 16-day pregnant mice compared with virgin litter-
mates using the Affymetrix mouse 430 chip. Setting the false discov-
ery rate (FDR) at 5%, our analysis revealed up- and downregulation 
of 141 and 147 unique genes, respectively, in the lungs of pregnant 
NOD/SCID mice, and of 352 and 389 genes, respectively, in the liver 
of pregnant animals (Supplemental Table 1). Interestingly, of the 
141 genes observed to be upregulated in pregnant mouse lungs, 13 
were shared (P = 4.1 × 10–20, Figure 8A) with the 50 top upregulated 
probesets in premetastatic lungs as published by Hiratsuka et al. 
(10): cyclin-dependent kinase inhibitor 1A/P21 (Cdkn1a); cathelicidin 
antimicrobial peptide (Camp); IL-1 receptor, type II (Il1r2); lysyl oxi-
dase (Lox); matrix metallopeptidase 8 (Mmp8); C-type lectin domain 
family 4, member d (Clec4d); neutrophilic granule protein (Ngp); S100 
calcium binding protein A8/calgranulin A (S100a8); S100 calcium 
binding protein A9/calgranulin B (S100a9); solute carrier family 2, 
member 3 (Slc2a3); schlafen 4 (Slfn4); elastin microfibril interfacer 2 
(Emilin2); and cDNA sequence BC055107. The term premetastatic niche 
Figure 6
NK cell impairment underlies increased metastasis in pregnant immunocompetent C57BL/6 mice. (A–C) Bioluminescence imaging after tail 
vein injection of 5 × 105 luciferase-expressing syngeneic, NK-sensitive B16.F10 melanoma cells (A) and NK-resistant RMA (B) and EL4 (C) 
lymphoma cells into 14-day pregnant and virgin C57BL/6 mice. **P < 0.01. (D) Standard 4-hour 51Cr release cytotoxicity assay with splenocytes 
extracted from poly(I:C)-stimulated 16-day pregnant and virgin C57BL/6 mice and Yac-1 target cells. Graph was adjusted for NK proportions in 
splenocytes, as determined by flow cytometry. 4 mice were used per condition.
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has been coined to describe a situation of increased metastatic per-
missiveness in organs of mice bearing aggressive primary tumors. 
Premetastatic niches are associated with the recruitment of bone 
marrow–derived cells (BMDCs), which are believed to play a key role 
in their establishment (9, 12). Upregulated genes common to preg-
nant and premetastatic lungs included several that encode myeloid 
cell–derived proteins. Lox, which has been proposed to be an essential 
constituent of premetastatic niches (12) and is functionally involved 
in BMDC recruitment, displayed a robust induction in the lungs of 
pregnant mice as determined by quantitative RT-PCR (Figure 8B). 
In parallel, gene expression profiling of pregnant mouse livers and 
comparative database analysis revealed significant overlaps among 
up- and downregulated genes in pregnant mouse liver tissue and 
previously described premetastatic livers from animals bearing 
xenotransplanted cecal tumors (ref. 28, Figure 8C, and Supplemen-
tal Figure 7A). Not surprisingly, there was a significant overlap in 
up- and downregulated genes between pregnant mouse lungs and 
liver (Figure 8D, Supplemental Figure 7B, and Supplemental Table 
2), and several of the shared upregulated genes could be associated 
with infiltration of myeloid cells — possibly MDSCs.
Figure 7
MDSC accumulation in 16-day pregnant mice correlates with increased permissiveness to metastasis. (A) Quantification of MDSCs in spleen, 
blood, lung, and liver of pregnant and virgin NOD/SCID mice by flow cytometry for (CD45+) CD11bhiGr-1+ cells. Overall CD11bhiGr-1+ cells and 
separate Gr-1hi and Gr-1lo subsets were determined. 4 mice were used per condition. *P < 0.05, **P < 0.01, ***P < 0.001. (B) Representative flow 
cytometry of spleen MDSCs. (C) T cell proliferation. MDSCs were isolated from splenocytes of pregnant and virgin C57BL/6 mice and T cells 
from virgin C57BL/6 spleen and lymph nodes by anti–Ly-6G and anti-CD90.2 magnetic beads, respectively. 3H-Thymidine incorporation assay 
of T cells after 3 days of MDSC coculture at the indicated ratios and in the presence of anti-CD3/anti-CD28–coated beads. *P < 0.05, **P < 0.01, 
unpaired 2-tailed t test. (D) MDSCs were isolated from splenocytes of pregnant and virgin NOD/SCID mice and NK cells from virgin NOD/SCID 
spleen by anti–Ly-6G and anti-CD49b magnetic beads, respectively. 51Cr release cytotoxicity assay was performed on Yac-1 target cells after 
20 hours of NK cell–MDSC coculture at a 1:1 ratio. Effector/target cell ratio was adjusted for NK proportions after coculture. (E and F) Tail vein 
injection of 5 × 105 luciferase-expressing B16.F10 tumor cells after in vivo depletion of MDSCs (CD11bhiGr-1hi fraction) by anti–Gr-1 antibody 
RB6-8C5. (E) Bioluminescence imaging. ***P < 0.001. (F) Lung histomorphometry. *P < 0.05, **P < 0.01.
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Finally, the prognostic value of differentially expressed genes in 
pregnant mouse lungs was tested on lung cancer microarray data 
for which patient outcome was available (29). This analysis was 
based on the hypothesis that stromal components — including 
immune cells — play an important role in primary tumor progres-
sion and are represented in transcriptome analyses of bulk tumor 
samples. Unsupervised hierarchical clustering of lung squamous 
cell and adenocarcinoma gene expression data (29) revealed that 
the downregulated genes in pregnant mouse lungs were able to 
divide patients into good- and poor-prognosis groups (Figure 8E). 
Mean fold change of each of the 91 human orthologs of downregu-
lated genes in pregnant mouse lungs was evaluated in both patient 
groups, and 51 (59%) of these genes showed lower expression levels 
in poor-prognosis patients (P = 0.0046).
Discussion
We have shown that murine gestation is associated with enhanced 
permissiveness for metastasis and that a candidate underlying 
mechanism is decreased NK cytotoxicity in the presence of an 
increased MDSC population. Although pregnancy, and multiple 
pregnancies in particular, confers protection against breast cancer 
development later in life (30), breast tumors that occur during preg-
nancy itself or within 5 years of giving birth display a high degree of 
aggressiveness, with rapid dissemination and metastasis (31). Mam-
mary gland involution has been suggested to be accompanied by 
tumor-promoting proinflammatory processes that could accelerate 
the initial steps of the metastatic cascade, including invasion and 
angiogenesis (32). However, pregnancy and related systemic adap-
tations could also contribute to increased tumor dissemination by 
facilitating later steps of the metastatic cascade, that is, once tumor 
cells have reached the lymphatic or blood circulation.
The only experimental work addressing specific metastasis-enhanc-
ing mechanisms in gestant mice has come to the conclusion that 
platelets from pregnant mice display greater and irreversible aggre-
gability that increases survival of injected tumor cells and leads to 
greater metastasis load (21). However, adoptive transfer of platelets 
isolated from pregnant mice could only marginally enhance metas-
tasis load in virgin mice (21). Accordingly, when we treated pregnant 
and virgin NOD/SCID mice with low–molecular weight heparin 
(LMWH) prior to tumor cell injection — at doses previously shown 
to abrogate tumor cell–induced thrombocytopenia, a measure for 
tumor cell–induced platelet aggregation (33) — we could only mar-
Figure 8
Gene expression profiling of pregnant versus virgin mouse lung and comparative dataset analysis reveal similarities with a premetastatic lung 
signature characterized by accumulation of myelomonocytic cells. RNA from 2 mice each (16-day pregnant and virgin NOD/SCID) were pooled 
for 1 Affymetrix mouse 430 chip, and 3 chips were used per condition. Differentially expressed genes in the lungs and livers were determined 
by the rank product method by setting the false detection rate (FDR) to 5%. (A) Comparative analysis of upregulated genes in pregnant mouse 
lung with upregulated genes in premetastatic lung (mice harboring aggressive versus benign primary tumors; data derived from the heatmap 
of Supplemental Figure 1D in ref. 10). Overlap P = 4.1 × 10–20. (B) Quantitative RT-PCR for Lox in lung RNA of 16-day pregnant (P-) and virgin 
(V-) NOD/SCID mice. (C) Comparative analysis of upregulated genes in pregnant mouse liver with upregulated genes (>2 fold change) in pre-
metastatic (untreated) liver (data derived from ref. 28). Overlap P = 1.3 × 10–6. (D) Commonly upregulated genes in pregnant mouse lung and 
liver. Overlap P = 1.1 × 10–11. (E) Unsupervised hierarchical clustering of lung cancer patients (from ref. 29) using orthologs of downregulated 
genes in pregnant mouse lung followed by Kaplan-Meier analysis of the 2 main patient groups (red, poor prognosis; blue, good prognosis). 
P = 0.0423. See also Supplemental Table 2.
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ginally decrease B16.F10 and HT1080 metastasis in pregnant mice 
(Supplemental Figure 8). This observation argues against a major 
metastasis-promoting effect of gestation-induced changes in tumor 
cell platelet aggregation, or the coagulation cascade, for that matter. 
In addition, neither serum nor plasma derived from pregnant mice 
had any direct positive effect on tumor cell proliferation, nor did s.c. 
tumors display differential growth. It therefore seemed more likely 
that the explanation for increased tumor dissemination during preg-
nancy lies in an altered tumor-host relationship. Because establish-
ment of a relationship with host tissues that is conducive to tumor 
cell survival and proliferation is key for metastatic development, the 
observed permissiveness for tumor dissemination displayed by tis-
sues during pregnancy may provide clues as to the identity of host 
factors that regulate tumor metastasis in general.
The obvious candidates among host factors that may determine 
metastatic tumor growth are the physical and chemical properties of 
tissues themselves and the state of the innate and adaptive immunity. 
Our observation of a rapid, but differential, clearing of tumor cells 
from the lung microvasculature of NOD/SCID mice, with the persis-
tence of more tumor cells during gestation, suggests a role for innate 
immunity. Although immunodeficient NOD/SCID mice were used 
in most experiments conducted in the present study, immunodefi-
ciency is not a prerequisite for increased metastasis in pregnant mice, 
since similar observations were made in fully immunocompetent 
A/Jax mice injected with syngeneic TA3 mammary carcinoma cells 
or with C57BL/6 mice challenged with B16 melanoma cells (ref. 21 
and the present study). Furthermore, metastasis was also enhanced 
in a spontaneous metastasis assay, most likely through promotion 
of the late steps of the metastatic cascade. It is well established that 
NK cells are among the main effectors of innate antitumor immune 
surveillance, and their importance in controlling tumor dissemina-
tion is widely accepted (22). On the other hand, pregnancy is a state 
of dampened cellular immunity, and NK activity in particular has 
been suggested to be decreased during murine (34) as well as human 
(35–37) pregnancies. Accordingly, we found a decrease in NK cell 
proportions in blood, spleen, lungs, and liver of 16-day pregnant 
mice and greatly reduced NK cell cytotoxicity. The total absence of 
NK cells in cg KO mice or the resistance of tumor cells to NK kill-
ing abolished the difference in metastasis growth between virgin and 
pregnant mice. Of note, although specific — but incomplete — NK 
cell depletion by AAGM1 antibody increased overall metastasis load, 
pregnant mice still developed more metastases than did their virgin 
counterparts, despite the persistence of more NK cells in the former. 
This finding suggests that decreased NK cell effector function, rather 
than merely decreased NK cell numbers, is responsible for enhanced 
tumor dissemination. We therefore provide the first evidence to our 
knowledge that the pregnancy-related decrease in systemic NK cell 
activity is responsible for the enhancement of host permissiveness to 
metastasis during murine gestation and may contribute to the worse 
prognosis of PABC, as hypothesized previously (20).
Why systemic NK cell activity decreases during pregnancy is 
unclear. It is possible that NK cell function is directly affected by the 
increased levels of steroid hormones during pregnancy (38) or that 
placenta-derived microparticles (17), exosomes (39), or soluble mol-
ecules such as sHLA-G (40) regulate their activity. Alternatively, preg-
nancy-related circulating factors could induce immunomodulatory 
changes in the microenvironment of target organs of metastasis. We 
therefore addressed possible mechanisms by investigating transcrip-
tome changes that occur during pregnancy. Gene expression profile 
analysis revealed that lungs and liver from pregnant mice bore strik-
ing similarities to lung (10) and liver (28) premetastatic niche signa-
tures. Commonly upregulated genes in pregnant and tumor-bearing 
mouse lung include Lox and several genes associated with myeloid 
cell recruitment. LOX is secreted by hypoxic breast tumors and accu-
mulates in the lungs of tumor-bearing animals prior to tumor cell 
dissemination, where it modifies basement membranes and contrib-
utes to BMDC recruitment (12, 41). Primary tumors are known to 
elaborate soluble factors (i.e., TDSFs) that drive the formation of 
privileged sites for the engraftment of disseminating tumor cells; 
moreover, TDSFs have been shown to orchestrate the expansion and 
activation of myeloid cell precursors that display suppressive activity 
for both adaptive and innate immunity (16). These MDSCs are char-
acterized by double-positive CD11b and Gr-1 staining in mice and 
accumulate in the primary tumor, tumor-draining lymph nodes, 
spleen, and lung of tumor-bearing animals. However, they have not 
been suggested to be constituents of premetastatic niches.
Premetastatic niches are characterized by the accumulation of 
BMDCs (42) that have further been characterized as CD11b+ cells 
(9, 10, 12) or Gr-1+ cells (28). To our knowledge, no experimental 
work thus far has shown an immunosuppressive function of these 
myeloid cells recruited to premetastatic sites, although a recent 
review raises the point that BMDCs may create “immune sanctuary 
sites” that favor survival and proliferation of engrafted metastatic 
cells (8). We provide evidence that CD11bhiGr1+ cells — in particu-
lar CD11bhiGr-1hi subsets — accumulate in pregnant mouse blood, 
spleen, lung, and liver, raising the possibility that the correspond-
ing immunosuppressive activity may have a blunting effect on NK 
cell function. The anti–Gr-1 antibody recognizes 2 distinct epitopes: 
Ly-6C, expressed on Gr-1lo cells; and Ly-6G, expressed on the Gr-1hi 
population. Gr-1hi cells of granulocytic morphology isolated from 
pregnant mice using anti–Ly-6G magnetic microbeads inhibited 
T cell proliferation and Il-2 secretion in addition to decreasing NK 
cell cytotoxicity in vitro compared with cells extracted from their vir-
gin counterparts. This immunosuppressive function strongly sup-
ports the notion that the myeloid cells accumulating during murine 
gestation are indeed MDSCs. Consistent with these observations, 
MDSCs isolated from tumor-bearing animals have been shown to 
decrease NK activity in a cell contact–dependent manner and to be 
responsible for increased tumor dissemination (24, 25).
Finally, the observation that in vivo depletion of MDSCs using anti–
Gr-1 antibody reduced metastatic tumor spread in pregnant mice, but 
not in virgin mice, confirms their mechanistic involvement in enhanc-
ing permissiveness to metastasis in pregnant mice. This finding and 
the results of the adoptive transfer experiment lend further support 
to the notion that Gr-1+ cells are functionally distinct in pregnant and 
virgin animals. This is in accordance with several reports that show 
immunosuppressive function of CD11bhiGr1+ cells derived from 
tumor-bearing, but not tumor-free, mice (24, 43).
Comparative analysis of differentially expressed genes of preg-
nant mouse lungs and liver and of premetastatic niches in organs 
of tumor-bearing mice (10, 28) revealed the upregulation of S100a8 
and S100a9 in all 4 gene expression profiles, representing situations 
of enhanced metastatic growth. Hiratsuka and colleagues have 
shown how these chemoattractants produced by cells of the myeloid 
lineage not only recruit additional BMDCs, but also attract circu-
lating tumor cells and enhance their invasiveness, thereby favoring 
lung colonization (10, 11). On the other hand, these chemotactic 
molecules are important inflammatory mediators that have been 
shown to contribute to MDSC accumulation and function in pri-
mary tumors (44, 45). The combined findings of S100a8 and S100a9 
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upregulation and MDSC accumulation in pregnant mouse lungs 
and liver further validate the hypothesis that MDSCs may partici-
pate in the elaboration of the premetastatic niche, thereby not only 
facilitating tumor progression at the primary site, but also enhanc-
ing the establishment of metastatic lesions.
In a clinical study, MDSC numbers have been shown to correlate 
with cancer stage and to influence prognosis (46). As the gene expres-
sion profile of pregnant mouse lung is suggested to reflect the accu-
mulation of these cells, we addressed the possibility that our differ-
entially expressed genes could be found in the stromal component of 
lung cancers and, when present, could correlate with worse outcome. 
Kaplan-Meier survival analysis of lung squamous cell and adenocar-
cinoma patients clustered into 2 groups according to expression of 
downregulated genes in pregnant mouse lung indicated that our 
signature performs well in predicting outcome. This observation is 
consistent with our previous work on a purely stromal cell–derived 
signature associated with invasive prostate cancer that was able to 
segregate primary prostate cancer samples with good prognosis from 
those with poor prognosis (47). Analysis of mean fold change in lung 
cancer samples revealed that the majority of downregulated genes in 
pregnant mouse lung were also less expressed in samples of patients 
clustering into the poor-prognosis group, which suggests that these 
genes may have metastasis and primary tumor suppressor functions 
when expressed by stromal cells.
In conclusion, we postulate that the many previously reported 
similarities in molecular and cellular mechanisms involved in can-
cer progression and placentation (48) should be extended to include 
a common mechanism for increasing permissiveness to metastasis 
in target organs by a process that involves, at least in part, accumu-
lation of MDSCs and suppression of NK cell activity. MDSC accu-
mulation has not to our knowledge been invoked previously in the 
context of pregnancy, but may well be a means whereby uterine as 
well as systemic maternal immune tolerance are regulated.
Methods
Animals. Female standard and cg KO NOD/SCID mice were obtained from 
in-house breeding at the ISREC mouse facility. C57BL/6 mice were from 
Jackson Laboratories, A/JOIaHsd mice from Harlan Laboratories. Female 
mice were between 8 and 10 weeks old at the beginning of experiments. 
Pregnancy was timed by checking for vaginal plugs early mornings for 4 
days after setting up breeding couples. Experiments involving mice were 
approved by the Etat de Vaud, Service Vétérinaire (Epalinges, Switzerland; 
authorization no. VD1477.1)
Reagents. The antibodies used were as follows: anti-ER MAb (RTU-ER-
6F11) from Novocastra; anti-PR MAb (PgR 63) and anti-human Ki67 MAb 
(M7240) from DakoCytomation; anti-GFP MAb (11 814 460 001) from 
Roche; rat anti-mouse CD11b-PE (M1/70), hamster anti-mouse CD49b-
PE (HMα2), rat anti-mouse CD16/32 (2.4G2), rat anti-mouse IL-2 (clone 
JES6-5H4), rat anti-mouse IL-10 (JES5-16E3), and rat anti-mouse IFN-γ 
(XMG1.2) from BD Biosciences — Pharmingen; rat anti-mouse NKG2D-
APC (CX5), rat anti-mouse NKp46–Alexa Fluor 647 (29A1.4), and mouse 
anti-mouse NK1.1-APC (PK136) from eBioscience; rat anti-mouse CD45–
PE-Cy7 (30-F11) from BioLegend; rat anti-mouse Gr-1–FITC (Ly-6G/Ly-
6C; RB6-8C5) from BioLegend and BioXCell (for in vivo depletion); rabbit 
AAGM1 from WAKO; and appropriate isotype controls and HRP-conju-
gated secondary antibodies. poly(I:C) was from Sigma-Aldrich). d-luciferin 
(firefly) potassium salt was from Biosynth. MACS cell sorting reagents 
were as follows: anti-CD49b–conjugated magnetic microbeads (DX5) 
and biotinylated anti–Ly-6G (1A8) antibody with anti-biotin–conjugated 
magnetic microbeads (Miltenyi Biotec). Collagenase II from Clostridium 
histolyticum was from Sigma-Aldrich. Recombinant human IL-2 was from 
ImmunoTools. Baytril antibiotics, 10% oral solution, were from Bayer.
Luciferase and GFP transduction of tumor cells. cDNA encoding firefly lucif-
erase (from pGL3) and enhanced GFP were cloned into second-generation 
lentivectors containing a EF1α or CMV promoter and puromycin or hygro-
mycin selection markers. B16.F10, LLC, TA3, HT1080, and MDA-MB-435 
cells were cultured in DMEM supplemented with 10% FBS. RMA, EL4, and 
Yac-1 cells were maintained in RPMI-1640 supplemented with 10% FBS.
Tumor cell injection, tumor resection, and adoptive transfer of MDSCs. For tail 
vein or s.c. injections, subconfluent tumor cells were detached with EDTA, 
washed, and resuspended in DMEM. For spontaneous metastasis assay, 
primary tumors (8–9 mm largest diameter) were resected 11 days after s.c. 
injection under general anesthesia. For MDSC adoptive transfer, cells were 
isolated with anti–Ly-6G microbeads, washed in PBS, and injected (6 × 106 
cells per animal) into the tail vein 20 hours prior to tumor cell injection. At 
least 5 animals per condition were used. Results shown are representative 
of at least 2 independent experiments.
Sublethal irradiation and NK cell and MDSC depletion. Sublethal γ irradiation 
of virgin and 14-day pregnant NOD/SCID mice was performed using a 137Cs 
source (1.6 Gy/min), and irradiation time was adjusted to reach a total dose 
of 2.7–3.0 Gy per animal. For NK cell depletion, rabbit AAGM1 (~400 μg) was 
injected i.v. 4 and 2 days prior to B16.F10 tail vein injection. Depletion effi-
ciency was tested by flow cytometry of blood samples. For MDSC depletion, 
anti–Gr-1 antibody (RB6-8C5; 250 μg per injection) was injected into the tail 
vein of virgin and pregnant mice, 3 and 1 days prior to tumor cell injection 
and 1 day later. Depletion efficiency was assessed on blood smears. For NK cell 
and MDSC depletion, appropriate control Igs — rabbit IgG and rIgG2b (clone 
LTF2), respectively — were injected into control animals. All animals were given 
antibiotic prophylaxis (300 μl Baytril in 250 ml drinking water).
Immunohistochemistry, lung histomorphometry, and blood leukocyte enumera-
tion. Formalin-fixed, paraffin-embedded lung tissue was stained for GFP, 
hKi67, ER, and PR according to the manufacturer’s recommendations. 
H&E staining was done according to standard procedures. 4–5 fields of 1 
H&E-stained lung section per animal were photographed at ×20 magnifi-
cation, and the percentage of lung surface occupied by metastatic lesions 
was determined as a pixel ratio in Photoshop CS. For quantification of leu-
kocytes, mouse blood (cardiac or tail vein) was collected into 1.2 ml EDTA 
monovette tubes (Sarstedt) and diluted 1:20 in Leukoplate (SOBODIA) 
before counting in a Neubauer chamber. Blood smears were stained with 
Giemsa-Wright (HemoQuick; Labo Moderne).
Mouse serum and plasma extraction and proliferation assay. Blood was obtained 
from pregnant and virgin mice by cardiac puncture. For serum extraction, 
whole blood was left to coagulate at room temperature for 15 minutes, then 
spun at 1,000 g for 15 minutes. For plasma preparation, blood was collected 
in a syringe containing 10 IE liquemin (Roche), diluted 1:1 with serum-free 
medium, and then spun at 1,500 g for 15 minutes. 3 × 103 B16.F10, HT1080, 
and MDA-MB-435 cells were seeded into wells of a 96-well plate 24 hours 
before the assay and serum-starved overnight. Mouse serum and plasma were 
diluted to 15% in serum-free medium and added to the tumor cells. MTT 
assay (Promega) was performed according to the product protocol after 48 
hours of incubation. Serum from 3 different mice was used per condition, 
and the experiment was conducted in triplicates for each cell line and serum. 
Plasma was prepared from 1 mouse per condition in duplicate wells.
Fluorescence stereomicroscopy. Mouse lungs were excised at given time points 
after tail vein injection of GFP-expressing tumor cells and immediately visu-
alized under a Leica MZ16 1FA fluorescence stereomicroscope with a fixed 
exposure time to compare pictures from pregnant and virgin mouse lungs.
In vivo bioluminescence imaging. After tail vein injection of luciferase-expressing 
tumor cells, total tumor cell load was assessed at various intervals by biolumi-
nescence imaging in an IVIS 200 series system (Xenogen) after i.p. luciferin 
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administration (75 mg/kg) and under isoflurane anesthesia. Several images 
over a 10- to 20-minute period were taken, and maximal photon flux over the 
whole body area was determined using Living Image Software (Xenogen).
Cell harvesting for cytotoxicity assays, flow cytometry, and cell isolation. Where 
indicated, mice were stimulated with 100 μg poly(I:C) i.p. 36 hours prior 
to splenocyte extraction. Virgin or 16-day pregnant NOD/SCID mice were 
sacrificed by cervical dislocation, and the heart was punctured for blood col-
lection into a 1.2-ml monovette (EDTA anticoagulation). Blood leukocytes 
were prepared by ammonium chloride buffer erythrolysis. Splenocytes were 
prepared by pressing the spleen through a 70-μm nylon mesh (BD Falcon). 
Platelets were removed by 2 rounds of slow spinning in PBS (300 g for 10 
minutes). For flow cytometry and magnetic bead cell sorting (MACS), sple-
nocyte suspensions were filtered through single-cell strainers. Lung and liver 
were minced with a razor blade prior to digestion in collagenase II (5 mg in 
5 ml RPMI-1640 with 10% FBS for 1 hour at 37°C), and single-cell suspen-
sions were obtained after sieving through a single-cell strainer.
51Cr release cytotoxicity assay. Splenocytes were harvested from pregnant and 
virgin mice as described above, and 51Cr release assays were performed accord-
ing to standard procedures. 106 Yac-1 cells were washed in complete medium 
and incubated with 50–100 μl Na251CrO4 for 1 hour at 37°C. Labeled cells 
were washed in complete medium and aliquoted into wells containing sple-
nocytes (1,000 Yac-1 cells/well). After 4 hours of incubation at 37°C, 51Cr 
release into the media was quantified using LumaPlate-96 plates (Perkin-
Elmer) and a Top-Count-γ-counter (PerkinElmer). 0% lysis was determined 
with complete medium only, 100% lysis by adding 100 μl of 1 M HCl to the 
target cells. Percent lysis was determined as (sample lysis — 0% lysis)/(100% 
lysis — 0% lysis). NK cell proportions of each sample were determined by flow 
cytometry, and effector/target ratios were adjusted accordingly.
NK cell, T cell, and MDSC isolation. NK cells, T cells, and MDSCs were 
isolated from virgin and 16-day pregnant NOD/SCID splenocytes (and 
lymph nodes for T cells) according to the manufacturer’s recommenda-
tions. Briefly, erythrocyte-free single-cell suspensions (typically ~1 × 108 
cells per condition) were washed and resuspended in MACS buffer and 
anti-CD49b–conjugated (NK cell isolation), anti-CD90.2–conjugated mag-
netic beads (T cell isolation), or biotinylated anti–Ly-6G antibody (MDSC 
isolation) mix and processed according to the manufacturer’s recommen-
dations prior to separation on LS columns in a magnet (Miltenyi Biotec).
NK cell–MDSC coculture. MACS-isolated NK cells from 3–5 virgin NOD/
SCID spleens and MDSCs extracted from 3–5 virgin and 3–5 pregnant 
mouse spleens were mixed at a 1:1 ratio (typically 1 × 106 cells each) and 
cocultured for 20 hours in RPMI-1640 plus 10% FBS and 250 ng/ml recom-
binant human IL-2 in a 24-well plate. Cells were aliquoted in triplicates 
into 96-well plates for 51Cr release cytotoxicity assay on Yac-1 target cells. 
Viability was assessed by trypan blue exclusion, and NK cell proportion was 
redetermined by flow cytometry after coculture.
T cell–MDSC coculture. MACS-isolated T cells from virgin NOD/SCID spleens 
and MDSCs from virgin and pregnant mouse spleens and lymph nodes were 
mixed at several ratios and cocultured in RPMI-1640 plus 10% FBS in a 96-well 
plate in the presence of anti-CD3/anti-CD28–coated beads (Dynal Biotech) at 
a 1:1 ratio for T cell stimulation. For 3H-thymidine proliferation assays, 3H-T 
was added (1 curie/well) after 3 days of co-culture, and the plate was read 18 
hours later in a Top-Count-γ-counter (PerkinElmer). For the CFSE prolifera-
tion assay, T cells were incubated in 1 ml of 2 μM CFSE solution (eBioscience) 
for 15 × 106 cells, 10 minutes at 37°C, before the coculture with virgin or preg-
nant MDSC. 4 days later, cells were analyzed by flow cytometry.
Flow cytometry. Blood leukocytes and single-cell suspensions from spleen, 
lung, and heart were prepared as described above. 106 cells were aliquoted 
into 5-ml tubes and washed with FACS buffer (PBS plus 3% FBS and 0.9% 
NaN3). Cells were preincubated with anti-CD16/CD32 and 2% goat serum 
for 10 minutes at 4°C. Staining was done for 30–45 minutes at 4°C. Antibody 
dilutions were as follows: CD45–PE-Cy7 (1:200), CD11b-PE (1:400), Gr-1–
FITC (1:300), CD49b-PE (1:400), NKp46–Alexa Fluor 647 (1:200), NKG2D-
APC (1:200), NK1.1-APC (1:200). Intracellular levels of T cell cytokines were 
assessed upon a 4-day T cell–MDSC coculture: 4 × 106 T cells were restimulat-
ed with 1 ml of 50 ng/ml PMA, 0.5 μg/ml ionomycin, and 10 μg/ml brefeldin 
A (all from Sigma-Aldrich) for 4 hours at 37°C. Cells were then permeabilized 
with FACS buffer plus 0.5% saponin before staining with IFN-γ–PE (1:200), 
IL-2–APC (1:100), and IL-10–PE (1:200) antibodies and flow cytometry analy-
sis on a FACSCalibur apparatus (BD), and FlowJo software (Tree Star Inc.) for 
image analysis and quantification of cell populations.
Affymetrix gene expression profiling and comparative analyses. Lungs and livers 
of pregnant and virgin mice were ground in liquid nitrogen and the powder 
homogenized by resuspension in RLT lysis buffer. RNA extraction was done 
using Qiagen RNAeasy Kit according to the manufacturer’s recommenda-
tions. Total RNA quality was verified by an Agilent RNA 600 nanoassay. 
cRNA synthesis, hybridization to an oligonucleotide array (GeneChip Mouse 
Expression Set 430; Affymetrix), and scanning were done by the DNA Array 
Facility of the University of Lausanne (DAFL). 3 chips were done per organ 
and per condition, with equal amounts of RNA from 2 mice pooled per chip. 
Normalization and background subtraction were performed with RMA (49), 
using the “affy” library (50) of Bioconductor (51). Differentially expressed 
genes were determined using rank-products (52), specifically the Bioconduc-
tor package RankProd (53). Statistical significance of the overlaps with pub-
lished gene signatures was computed with a 1-tailed exact Fisher’s test with 
Bonferroni correction where multiple testing was performed. Microarray data 
were deposited in GEO (accession no. GSE18907).
Quantitative real-time PCR. cDNA was obtained using MMLV reverse tran-
scriptase and RNase H minus (Promega). Real-time PCR amplification was 
done using specific intron spanning primers and appropriate Universal 
Probe library probe for Lox in an ABI Prism 7700 instrument (Applied Bio-
systems). Relative quantification of target, normalized with an endogenous 
control (18s), was done using a comparative Ct method.
Statistics. Graphs and statistics were done using GraphPad Prism 5.0 soft-
ware. Mean ± SEM is depicted in all graphs. Statistical significance was 
determined by 2-way ANOVA for repeated measurements with Bonferroni 
post-test for bioluminescence data; by unpaired 2-tailed t test for lung 
histomorphometry, primary tumor weight, MTT assay, and flow cytom-
etry results comparing 2 groups; and by 1-way ANOVA with Bonferroni 
post-test for lung histomorphometry comparing 4 groups. A P value less 
than 0.05 was considered significant.
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